Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed squamous cell carcinoma or adenocarcinoma of the thoracic esophagus (below 20 cm) or gastroesophageal junction~  * Surgically resectable disease (T1-3; NX, N0, or N1; M1a)~ * T4 tumors that are not unequivocally unresectable allowed~ * Celiac lymph node (stations 15-20) involvement allowed~* Must be considered a potential surgical candidate by a thoracic or general surgeon~* No supraclavicular lymph node involvement by palpation, biopsy, or radiograph (greater than 1.5 cm)~* No distant metastases~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~  * Patients with ECOG 2 must be considered good candidates for study by treating oncologists~Life expectancy~* At least 12 weeks~Hematopoietic~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* AST no greater than 3 times ULN~Renal~* Creatinine no greater than 1.5 times ULN~Cardiovascular~* No New York Heart Association class III or IV heart disease~Other~* No uncontrolled infection~* No other severe underlying disease that would preclude study participation~* No grade 2 or greater peripheral neuropathy~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy for esophageal cancer~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy to anticipated fields of study radiotherapy~Surgery~* Not specified~Other~* No concurrent diuretics~* No concurrent amifostine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- carboplatin + paclitaxel + fluorouracil + radiation + surgery (Type: EXPERIMENTAL): Patients receive carboplatin IV and paclitaxel IV over 3 hours on days 1 and 22 and fluorouracil IV continuously on days 1-42. Beginning on day 1 of chemotherapy, patients undergo radiotherapy to the esophagus 5 days a week for 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease at 4-8 weeks after completion of radiotherapy undergo esophagectomy and complete dissection of the mediastinal and perigastric lymph nodes. Beginning 8 weeks after surgery, patients who underwent curative resection may receive a maximum of 2 additional courses of paclitaxel and carboplatin in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, before chemotherapy on days 1 and 22, and within 2 weeks before surgery.~Patients are followed every 3 months for 4 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).